39 results about "Immunocompatibility" patented technology

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The invention discloses a method for preparing blood vessel middle layer scaffold material used for biodegradable tissue engineering, comprising the steps: human-like collagen is dissolved to be solution with the mass percent concentration of 1-3% by distilled water; degumming silk protein is dissolved in 30-50% of CaCl2 solution to be dialyzed to obtain the silk protein solution with the concentration of 2-4%; the two obtained solutions are evenly mixed together, mixed with glutaric dialdehyde water solution with the mass percent concentration of 20-50% and stirred; after being filtered, the obtained solution is processed by vacuum defoamation; the mixed solution is injected into a tubular shape mould to be processed by cross linkage at the temperature of 4 DEG C for 2 days, and then put into a refrigerator with the temperature of -80 DEG C to be frozen and dried, so that the blood vessel middle layer scaffold is prepared. Compared with the prior art, the prepared scaffold material has excellent mechanical capacity, biocompatibility, blood compatibility and immunity compatibility as well as lower immunity rejection reaction, thoroughly avoids the virus hidden trouble which is inevitable for animal collagen, and greatly improves the safety.

The present invention relates to a method for dedifferentiating somatic cells using microvesicles derived from embryonic stem cells. More particularly, the present invention relates to a method for preparing pluripotent stem cells by treating somatic cells with a composition having microvesicles derived from embryonic stem cells. The method for preparing pluripotent stem cells according to the present invention effectively facilitates the dedifferentiation of somatic cells without side-effects using the microvesicles, and further, is expected to be significantly useful in the development of cell therapy products having immune-compatibility suitable for specific individuals.

This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.

The present disclosure relates to a method for inducing pluripotent stem cells by inducing reprogramming and / or dedifferentiation of differentiated adult cells using shikimic acid, a plant extract or plant stem cells containing shikimic acid and an extract of dedifferentiated stem cells (callus), pluripotent stem cells prepared by the method and a composition containing the pluripotent stem cells. In accordance with the present disclosure, ethical concerns implicated with the use of eggs to prepare pluripotent stem cells such as embryonic stem cell can be resolved. And, because the plant stem cell extract unharmful to human is used, pluripotent stem cells with proven safety can be prepared and they may be used to develop immunocompatible cell therapy agents suited for individuals. In addition, by pluripotent stem cells from individuals having diseases, the present disclosure will be very useful in studying the cause of diseases and devolving therapeutic strategy.

Immunocompatible pluripotent stem cells (pSCs), which include cells compatible with different patient populations or patient-specific cells, find wide application in regenerative medicine therapies. Described herein are immunocompatible pSCs generated using techniques such as parthenogenesis resulting in cells possessing desired haplotypes of reduced zygosity, antigenically compatible with multiple patient populations, or nuclear transfer allowing generation of patient-specific cells. Methods described herein related to parthenogenesis, nuclear transfer, or pSC cell line generation. Also described herein are compositions of immunocompatible pSCs and cell lines generated by the aforementioned techniques.

The invention, which belongs to the field of pharmacy, relates to a D8 polypeptide and a brain-targeted drug delivery system thereof, particularly to, a specially-acetylcholine-receptor-targeted D8 polypeptide with a biomembrane-crossing effect and a brain-targeted drug delivery system thereof. According to the invention, a nano-carrier modified by the polypeptide molecule D8 is specifically combined or taken by a positive cell expressing an acetylcholine receptor to realize strong brain targeting and imaging functions and the capability of affinity with a biomembrane barrier to form a cell. With a constructed nano drug delivery system, such as lipidosome, polymer micelle, a polymer disc, and a nanoparticle, an entrapped model drug can be delivered to a brain tissue and a cell expressing an acetylcholine receptor effectively, so that the treatment effect to diseases in brain can be improved obviously; the side effect is low; and the immunocompatibility is high. Therefore, the D8 polypeptide and the brain-targeted drug delivery system thereof have the broad application prospects in fields of diagnosis and targeted therapy of intracerebral diseases such as intracerebral tumors.

The invention discloses a method for preparing biomimetic artificial bone materials for biodegradable tissue engineering. The method comprises the following steps: adding a hydroxyapatite suspension to a human-like collagen solution; adding Genipin for crosslinking; performing vacuum freeze-drying to obtain human-like collagen / hydroxyapatite powder; adding the human-like collagen / hydroxyapatite powder to a chitosan solution; using an NaOH solution to adjust the pH of the solution to 7.0; repeatedly adding the human-like collagen solution and the chitosan solution; adding a Genipin solution for crosslinking; freeze-drying a mixed solution; inoculating the obtained material with BMSCs of which the cell density is 5*10 cells / cm; performing culture for 1 to 10 days; using an induction medium to culture BMSCs cells so as to induce the BMSCs cells to differentiate towards an osteogenesis direction; and forming bone repair composite materials with bone inducing activity. The artificial bone materials prepared by the method are excellent in bone inducing activity and immune compatibility, thereby thoroughly putting an end to inevitable viral hidden trouble of animal collagen scaffold materials and greatly improving use safety.

A method for inducing tailored pluripotent stem cells by reprogramming differentiated cells of an adult by using an extract of plant stem cells and plant dedifferentiated stem cells (callus); pluripotent stem cells produced by means of the method; and a cell therapy agent comprising the pluripotent stem cells are disclosed. It is possible to overcome ethical problems since eggs are not used in the making of pluripotent stem cells having abilities like embryonic stem cells. It is possible to produce pluripotent stem cells of ensured safety because a plant stem cell extract which above all has been verified to be harmless to the body is used. It is possible to develop an immunocompatible cell therapy agent tailored to different individuals.

The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and / or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and / or regulatory T-cells (Treg, CD4+CD25+foxp3+ cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.

A polymer matrix is provided comprising an amine-containing polyampholyte covalently crosslinked with an electrophilic polymer to yield an immunocompatible polymer matrix. A hydrogel system incorporating the polymer matrix is also provided.